Ursodeoxycholic acid improves pregnancy outcome in patients with intrahepatic cholestasis during pregnancy: A protocol for systematic review and meta-analysis

Intrahepatic cholestasis of pregnancy (ICP) is a common complication in the third trimester of pregnancy, which may result in premature delivery, fetal distress, stillbirth, and other adverse pregnancy outcomes. Ursodeoxycholic acid (UDCA) is a first-line treatment for ICP and has been controversial...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2021-01, Vol.100 (4), p.e23627-e23627
Main Authors: Wang, Yan, Peng, Xiabiao, Zhang, Yongyuan, Yang, Qiuchen, Xiao, Yuhong, Chen, Yuezhou
Format: Article
Language:English
Subjects:
Cholagogues and Choleretics - therapeutic use
Cholestasis, Intrahepatic - drug therapy
Female
Fetal Distress - epidemiology
Fetal Distress - etiology
Humans
Incidence
Infant, Newborn
Meta-Analysis as Topic
Pregnancy
Pregnancy Complications - drug therapy
Pregnancy Outcome - epidemiology
Premature Birth - epidemiology
Premature Birth - etiology
Prenatal Care - methods
Research Design
Stillbirth - epidemiology
Study Protocol Systematic Review
Systematic Reviews as Topic
Treatment Outcome
Ursodeoxycholic Acid - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intrahepatic cholestasis of pregnancy (ICP) is a common complication in the third trimester of pregnancy, which may result in premature delivery, fetal distress, stillbirth, and other adverse pregnancy outcomes. Ursodeoxycholic acid (UDCA) is a first-line treatment for ICP and has been controversial in improving adverse pregnancy outcomes. The purpose of this protocol is to systematically evaluate the effect of UDCA on pregnancy outcomes in patients with intrahepatic cholestasis during pregnancy. To search the databases PubMed, Embase, Web of Science, the Cochrane Library, CNKI, WanFang, VIP, CBMDIsc by computer, then to include randomized controlled clinical studies on UDCA for treatment of intrahepatic cholestasis during pregnancy from the establishment of the database to October 1, 2020. Two researchers independently extract and evaluate the data of the included studies, and meta-analysis is conducted on the included literatures using RevMan5.3 software. This protocol evaluates the outcome of UDCA in improving ICP by incidence of postpartum hemorrhage in pregnant women preterm birth rates meconium contamination rate in amniotic fluid incidence of fetal distress scale of newborns scoring
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000023627